B of A Securities Maintains Buy on bluebird bio, Raises Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Jason Gerberry has maintained a Buy rating on bluebird bio (NASDAQ:BLUE) and increased the price target from $11 to $12. This adjustment reflects a positive outlook on the company's stock, suggesting potential upside from the current trading levels.
December 11, 2023 | 4:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
B of A Securities analyst has reiterated a Buy rating on bluebird bio and raised the price target to $12, indicating a bullish stance on the stock's future performance.
The increase in price target by a reputable analyst typically signals confidence in the company's prospects, which can positively influence investor sentiment and potentially lead to a short-term increase in the stock price. Given that the rating is a Buy and the target has been raised, this suggests a stronger conviction in the company's potential for growth.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100